CD8A and neoplasm: Ghiringhelli et al. demonstrated that chemotherapy-treated dying tumor cells can activate the NLRP3 inflammasome in DCs and that a functional NLRP3 inflammasome in DCs is required for tumor-specific CD8+ T cell priming (217).